Grants for Nonprofits - Health

This funding opportunity supports collaborations between academic institutions and industry to develop innovative technologies that improve disease diagnosis, treatment, and management, particularly for underserved populations.

This funding provides financial support to licensed treatment programs in California to expand services for opioid use disorder, particularly in underserved areas and for vulnerable populations.

This funding opportunity provides up to $1 million over two years to local nonprofits in Summit County for collaborative projects that address housing, mental health, and public safety while promoting diversity and sustainable community impact.

The Home Office Giving Program aims to enhance the Greater Richmond, Virginia area, making it an ideal place for families by supporting underserved youth and/or adults in specified localities. Eligible nonprofits must focus on promoting education and workforce success, health and wellness, or fostering resilient communities. They should also demonstrate a clear need for their program based on demand or the population served. Grant renewed every year. Grant annual opening/ closing deadline: September 1st to October 15th, with nonprofits being informed of their application status by the following spring.

Grants are aimed at supporting and promoting quality educational, human services, and health care programming for underserved populations, with a special focus on organizations that serve city of Lynn and the North Shore of Massachusetts. Requests for general operating support, program support, and small, program-related capital expenses are encouraged.

This program provides matching funds to municipalities and nonprofit organizations in Massachusetts for projects that preserve and enhance the history and experiences of veterans.

This funding opportunity supports research into how certain diabetes medications may influence cancer risk, encouraging studies that explore the underlying biological mechanisms involved.

This funding opportunity is designed for healthcare institutions and organizations in the U.S. to improve the management and outcomes of migraine patients in emergency departments.

Wastewater Based Epidemiology involves analyzing the chemical and biological components present in wastewater to gather information about the health and behavior of a population. Localities have used it to monitor drug consumption patterns in their communities and understand local drug usage trends. It holds promise for monitoring the emergence and geographic distribution of novel substances often referred to as emerging threats. In FY2023, the United States Government funded pilot WBE drug projects that collected wastewater samples in over 70 United States communities representing tens of millions of Americans. The samples were analyzed for parent drugs, such as fentanyl and methamphetamine, and metabolites. Researchers shared results with participating sampled communities, local and state partners, and to a limited extent, the government sponsors.

This grant provides funding for innovative research using invasive brain recording and stimulation techniques in humans to improve understanding of the neural circuits involved in mental health disorders.

The purpose of the NINDS Research Program Award (RPA) is to provide longer-term support, and increased freedom and flexibility, to Program Directors (PDs)/Principal Investigators (PIs), to allow them to redirect their time away from the administrative burden of writing and managing multiple grant applications and towards engaging in the lab. This RPA affords investigators at most career stages the opportunity to advance their long-term research goals, rigorously explore exciting research opportunities, and mentor students and postdoctorates, which support and align with the mission of NINDS. RPAs will support the overall research programs of NINDS-funded investigators for up to 8 years, at a level commensurate with a PD/PIs recent NINDS support (Part 2, Section II). This funding stability will provide eligible investigators increased security, allowing them to undertake research projects that require a longer timeframe or to embark upon research that breaks new ground. Research activities outside of the NINDS mission, or traditionally supported by another NIH Institute or Center, will not be considered through this program. Benefits of the RPA include: A more stable funding environment, facilitating the pursuit of longer-term research goals; Flexible funding, enabling investigators to pursue research opportunities as they arise, not tied to specific aims; Reduced time spent writing grant applications and managing multiple grant awards, allowing investigators to spend more time conducting and overseeing research; More time for PDs/PIs to mentor and foster a diverse workforce in their laboratories. NINDS is committed to enhancing the diversity and inclusiveness of the neuroscience workforce. A diverse NIH-supported scientific workforce, including individuals from underrepresented groups, fosters scientific innovation, enhances global competitiveness, contributes to robust learning environments, and improves the quality of the research. See the Notice of NIH

This funding opportunity supports researchers conducting observational studies to improve understanding and treatment of musculoskeletal, rheumatic, and skin diseases, with a focus on patient outcomes and disease progression.

The Loudoun County Disability Services Board sponsors an awards program, the Full Accessibility and Inclusion: Moving toward Equity (FAIME) Awards, designed to recognize businesses and organizations that demonstrate a strong commitment to the full inclusion of people with disabilities in the workplace. This program aligns with the broader mission of promoting equity and accessibility for individuals with disabilities within the community. The awards are given to those who go above and beyond in fostering an inclusive workplace and business model. The target beneficiaries of this program are people with disabilities who seek employment and professional development opportunities. The program aims to increase the recruitment, hiring, training, and promotion of people with disabilities, ultimately enhancing their participation in the workforce. The impact goals include creating more inclusive work environments and business models that provide equal opportunities for individuals with disabilities. The FAIME Awards program prioritizes businesses and organizations that actively demonstrate a commitment to hiring people with disabilities, providing necessary accommodations in the workplace, and offering professional development opportunities to help them grow their skills. The focus is on encouraging practices that support the long-term career growth and integration of people with disabilities. Expected outcomes of this awards program include a greater number of businesses and organizations adopting inclusive hiring and workplace practices. Measurable results could include an increase in the employment rate of people with disabilities in Loudoun County, a rise in the number of businesses offering accommodations, and a measurable improvement in professional development opportunities available to this demographic. The program serves as a strategic initiative by the Loudoun County Disability Services Board to drive systemic change and foster a more equitable and inclusive society through the workplace.

The Lola Wright Foundation is a private, non-profit charitable foundation dedicated to supporting community-based organizations. Its overarching mission is to bolster entities that are granted tax exemption under the Internal Revenue Code, Section 501(c)(3), particularly those operating primarily within a 50-mile radius of Austin, Texas. This geographic focus ensures that the Foundation's efforts are concentrated on local community development and impact, aligning its grant-making activities directly with the needs of the Austin area. The Foundation targets a diverse range of beneficiaries, including children and youth, individuals in need of public health and human services, and groups benefiting from education and community development initiatives. It also extends its support to arts and culture organizations. Specific populations like minorities, the homeless, and the elderly are explicitly mentioned as funding emphases, indicating a strategic priority to reach vulnerable and underserved segments of the community. The impact goals revolve around fostering social well-being, promoting health, supporting educational advancement, and enriching cultural life within its defined geographic area. The Foundation's priorities and focuses are clearly delineated across several key fields of interest: Children and Youth, Public Health and Human Services, Education and Community Development, and Arts and Culture. These areas represent the strategic pillars of its grant-making. The Foundation generally does not provide funding for day-to-day operating costs or expenses, preferring to support projects and initiatives that align with its broader objectives. This suggests a focus on sustainable, project-based impact rather than routine operational support. While specific expected outcomes and measurable results are not explicitly detailed as quantitative metrics in the provided text, the Foundation's theory of change appears to be rooted in strengthening community infrastructure through strategic investment in key social, health, educational, and cultural sectors. By supporting 501(c)(3) organizations, it aims to empower local groups to address pressing community needs. The restriction on reapplying for a grant for at least twelve months after receiving one suggests a desire to allow funded projects sufficient time to demonstrate impact before further consideration, promoting a cycle of focused investment and evaluation.

The Islamic Scholarship Fund (ISF) initiated the Film Grant program in 2014 with the core mission of creating a stronger narrative of Muslim stories and supporting Muslim filmmakers. This aligns directly with ISF's broader goal of changing the narrative and empowering Muslim voices. Since its inception, the program has grown significantly, awarding $510,000 to promising filmmakers and cultivating a pipeline of over 96 American Muslim filmmakers, demonstrating a clear commitment to fostering talent within the community. The grant specifically targets emerging Muslim filmmakers who are creating artistic, engaging, and positive stories about their community. This focus on emerging talent aims to diversify storytelling and empower new voices within the film industry. The program's impact goals include not only providing financial support but also offering crucial mentorship and networking opportunities from industry professionals, thereby contributing to the long-term career advancement and success of grant recipients. The program prioritizes projects that are either narrative or documentary, and it supports various formats including feature-length films, short films, and animation (web series are not accepted). Key focuses for eligibility include that the filmmaker must be a U.S. citizen, at least one member of the creative team (producer or director) must be Muslim, and the content must feature American Muslim characters or themes. Additionally, at least 50% of the project must be filmed in the U.S., emphasizing the grant's commitment to American Muslim storytelling. Expected outcomes of the ISF Film Grant include the production of high-quality films that offer positive and authentic portrayals of American Muslim experiences. Measurable results include the number of grants awarded (ranging from $5,000 to $15,000 per category), the provision of creative support, and the facilitation of networking opportunities. The ISF also organizes screenings after film completion, providing a platform for visibility and audience engagement. This comprehensive approach reflects ISF's strategic priority of cultural empowerment through media, aiming to shift perceptions and build understanding through the power of storytelling.

This funding opportunity is designed to establish a center that will coordinate and advance research on whole person health by integrating diverse biomedical knowledge and fostering collaboration among researchers.

This funding opportunity supports researchers with active NCI U01 awards who want to integrate innovative cancer research technologies to improve their studies and advance cancer prevention, detection, diagnosis, and treatment.

This funding opportunity supports research to uncover genetic factors related to mental disorders in diverse populations, particularly those of non-European ancestry, while promoting community engagement and career development for early-career researchers.

Allergic reactions to drugs and vaccines are a serious public health concern. For the purpose of this notice of funding opportunity (NOFO), allergic reactions include not only IgE-mediated reactions, but other immune-mediated and largely unpredictable drug and vaccine reactions. Based on data from 2013-2014, each year in the United States there are an estimated 200,000 emergency department visits for adverse events related to antibiotics. In children 5 or younger, antibiotics cause more than half (56%) of estimated emergency department visits for adverse drug events and 82% of these visits are due to allergic reactions. Allergic reactions to antibiotics include immediate life-threatening reactions such as anaphylaxis, severe cutaneous reactions including Toxic Epidermal Necrolysis and Drug Reaction with Eosinophilia and Systemic Symptoms, and less severe reactions that still limit further use of the drugs. A label of antibiotic allergy leads to the use of alternative, frequently more expensive antibiotics, often with lower efficacy, which may contribute to antibiotic resistance as well as increased mortality and morbidity in hospitalized patients. While allergic reactions to vaccines are less common, the inability to receive a vaccine due to an allergy is problematic to the individual, and the perceived risk of allergic reactions to vaccines contributes to vaccine hesitancy creating a public health issue. Objectives The objective of this NOFO is to solicit innovative projects to study the mechanisms and management of vaccine or antibiotic drug allergy (research on allergic responses to anti-viral, anti-fungal and anti-parasitic drugs will also be considered). The scope of research into antibiotic or vaccine allergic reactions includes, but is not limited to, the following: IgE-mediated and other mechanisms of immediate allergic antibiotic or vaccine reactions Non-IgE-mediated urticarial reactions to antibiotics or vaccines Delayed-type hypersensitivity reactions to antibiotics or vaccines Severe cutaneous adverse antibiotic or vaccine reactions Biomarkers to identify people at risk for reaction or to confirm reactions to specific antibiotics or vaccines Host factors that may predispose to allergic reactions including, but not limited to, host microbiome, genetics, or inflammatory conditions Mechanisms by which specific infections may increase the risk of an allergic reaction to an antibiotic or vaccine Immunomodulatory approaches to treating or preventing immunologic adverse antibiotic or vaccine reactions A secondary objective of this NOFO is to expand the number of investigators working in the field of vaccine and antibiotic drug allergy. Early-stage investigators are encouraged to apply. UG3/UH3 phase transition and Milestones This funding opportunity is designed as a two-stage cooperative agreement in which Project Scientists from NIAID will work with the investigative team. It will support projects that are organized into a two-year UG3 phase followed by a three-year UH3 phase. The UG3 phase may include pilot, observational, or hypothesis-generating high-risk projects. Preliminary data may be helpful but are not required. The use of electronic health records to identify potential participants for mechanistic studies is allowed. The use of human samples such as those related to clinically indicated and routinely used interventions or tests is encouraged. The UG3 must include milestones to determine the success of the project at the end of this phase. Milestones may be negotiated or re-negotiated after award as this program includes the flexibility to quickly revise milestones and/or aims within the scope of the original peer-reviewed application. Following the completion of the UG3 phase, NIAID staff will review the progress made and make the determination on whether the project will continue to the UH3 phase. NIAID support for the UH3 is contingent upon progress made during the UG3 phase, meeting the milestones, programmatic priorities, the original UG3/UH3 peer review recommendations, and the availability of funds. Some projects might not transition from the UG3 to the UH3 phase. Projects supported by the UH3 phase are required to be hypothesis driven, mechanistic, and extend the work initiated by the UG3 phase. Program Director/Principal Investigator (PD/PI) Meeting Attendance A kick-off meeting and annual meetings will be organized by NIAID to facilitate interactions among recipients to share approaches, data, and methods, with the aim of developing a cadre of dedicated researchers to conduct antibiotic and vaccine allergy and advance mechanistic research. These meetings will convene yearly in the Rockville, Maryland area and will be held in person, though a virtual component will be available to allow broader participation from laboratory members. The PD/PI from each award is expected to attend the kickoff meeting and annual meetings in person. Applications that propose the following topics will be considered non-responsive and will not be reviewed: Adverse drug reactions that are predictable and/or related to pharmacologic properties of the drug such as toxicity or overdose Investigation into drugs that are not antibiotics or vaccines (however research on anti-viral, anti-fungal and anti-parasitic drugs is allowed) Investigations into Guillain-Barré Syndrome or drug-induced autoimmune reactions Investigations of central nervous system and other neurologic adverse responses Investigations into the pathogens rather than host allergic responses to the antibiotics or vaccines Applications that do not propose mechanistic research in the UH3 phase Vaccines that are administered via a route that is not the same route of administration as approved by the FDA Vaccines that are used as an immunotherapeutic (e.g. allergen immunotherapy) HIV/AIDS research

This funding opportunity supports collaborative research teams of diverse experts to tackle ambitious challenges in dental, oral, and craniofacial science, focusing on innovative solutions like non-opioid pain therapies and health disparity-reducing technologies.